Cargando…
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes
BACKGROUND: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to...
Autores principales: | Gibson, EJ, Begum, N, Koblbauer, I, Dranitsaris, G, Liew, D, McEwan, P, Tahami Monfared, AA, Yuan, Y, Juarez-Garcia, A, Tyas, D, Lees, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848668/ https://www.ncbi.nlm.nih.gov/pubmed/29563820 http://dx.doi.org/10.2147/CEOR.S144208 |
Ejemplares similares
-
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
por: Gibson, Eddie, et al.
Publicado: (2017) -
Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma
por: Gibson, Eddie J, et al.
Publicado: (2020) -
Ironing out exercise on immuno-oncological outcomes
por: Soh, Janjira, et al.
Publicado: (2022) -
Virus-Based Immuno-Oncology Models
por: Sitta, Juliana, et al.
Publicado: (2022) -
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)